Furthermore, IFN-α treatment can prevent disease initiation in secondary transplantation, suggesting that IFN-α treatment has a direct effect on MPN disease-initiating cells (24, 25). This evidence concerns the gene IFNA1 and myeloproliferative neoplasm.